Answers are grounded in this paper and cite their sources.
Management of clinically suspicious lateral pelvic lymph nodes after neoadjuvant therapy for rectal adenocarcinoma remains one of the most debated issues in contemporary rectal cancer surgery. While selective lateral pelvic lymph node dissection (LPLND) may improve compartment-specific disease control in patients with persistent or high-risk lateral nodal disease, its routine or selective use remains controversial because of concerns regarding operative burden, treatment selection bias, and uncertain oncologic benefit in the era of modern MRI-guided neoadjuvant strategies. We conducted a systematic review and meta-analysis of comparative studies evaluating LPLND versus omission after neoadjuvant therapy in rectal adenocarcinoma with clinically suspicious lateral pelvic nodes. PubMed/MEDLINE, Scopus, and Web of Science were searched, yielding 1,021 records. After deduplication and screening, three eligible comparative studies were included. Random-effects meta-analyses were performed. Risk of bias was assessed using ROBINS-I, certainty of evidence with GRADE, and sensitivity analysis with a leave-one-out approach. Three studies comprising 301 patients were included, with 139 patients in the LPLND group and 162 patients in the no-LPLND group. The effect of LPLND on lateral/local pelvic recurrence was highly uncertain (RR 0.66, 95% CI 0.12-3.59), because the wide confidence interval encompassed both a substantial reduction and a substantial increase in recurrence risk. No statistically significant differences were observed in pathologic nodal positivity (RR 1.24, 95% CI 0.92-1.68), advanced residual tumor stage (RR 0.95, 95% CI 0.79-1.13), or systemic/distant recurrence (RR 1.06, 95% CI 0.62-1.83). Operative time (MD 87.27 minutes, 95% CI 47.98-126.56) and length of hospital stay (MD 1.00 day, 95% CI 0.30-1.71) were significantly greater with LPLND, whereas estimated blood loss was not significantly different (MD 119.18 mL, 95% CI -15.93 to 254.30). Disease-free and overall survival could not be quantitatively synthesized because comparable time-to-event estimates were unavailable. Leave-one-out sensitivity analysis did not resolve the substantial imprecision of the primary outcome. Selective LPLND was associated with greater operative burden, but the available evidence was insufficient to determine its effect on lateral/local pelvic recurrence with clinical confidence. No statistically detectable differences were observed across the pooled recurrence and pathologic endpoints; however, disease-free and overall survival could not be quantitatively evaluated. These findings should be interpreted as a state-of-the-evidence summary and do not support definitive practice-changing recommendations.
No takes yet. Share an insight, caveat, or question.
Ullah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: